Abstract: A system and method for testing the integrity of a vehicle testing/diagnostic system is provided. Examples of vehicle testing/diagnostic systems may include any equipment (portable or stationary) found in an automotive maintenance and/or testing environment (or other environment) that is capable of communicating with vehicle on-board diagnostic (OBD) systems. Prior to conducting an OBD test on one or more vehicles, an integrity testing system interfaces with a vehicle testing/diagnostic system to determine whether the vehicle testing/diagnostic system is capable of communicating via one or more predetermined communications protocols.

Abstract: A system and method for testing the integrity of a vehicle testing/diagnostic system is provided. Examples of vehicle testing/diagnostic systems may include any equipment (portable or stationary) found in an automotive maintenance and/or testing environment (or other environment) that is capable of communicating with vehicle on-board diagnostic (OBD) systems. Prior to conducting an OBD test on one or more vehicles, an integrity testing system interfaces with a vehicle testing/diagnostic system to determine whether the vehicle testing/diagnostic system is capable of communicating via one or more predetermined communications protocols.

Abstract: A system and method for testing the integrity of a vehicle testing/diagnostic system is provided. Examples of vehicle testing/diagnostic systems may include any equipment (portable or stationary) found in an automotive maintenance and/or testing environment (or other environment) that is capable of communicating with vehicle on-board diagnostic (OBD) systems. Prior to conducting an OBD test on one or more vehicles, an integrity testing system interfaces with a vehicle testing/diagnostic system to determine whether the vehicle testing/diagnostic system is capable of communicating via one or more predetermined communications protocols.

Abstract: An approach to abstracting the circuit switched nature of the public switched telephone network (PSTN) by using VoIP to provide voice actuated services is disclosed. By carrying a telephone call using VoIP technology for a short distance (frequently within a server room) significant benefits to call handling and capacity management can be obtained. Specifically, a PSTN-to-IP gateway is used to receive (and place) calls over the PSTN and route those calls internally to servers over an IP network in a packet switched format. A number of computer systems can receive and handle the calls in the IP format, including: translating the packets into an audio format suitable for speech recognition and creating suitable packets from computer sound files for transmission back over the PSTN.

Abstract: The invention relates to the identification and cloning of a two novel full-length human SLAP-2 variants and their encoded polypeptides, hSLAP-2v3 and hSLAP-2v4. hSLAP-2v3 and hSLAP-2v4 are members of the SLAP family of adapter proteins and are involved in the negative regulation of intracellular T-cell signal transduction. The invention further relates to the use of these novel hSLAP-2v3 and hSLAP-2v4 polynucleotides and their encoded polypeptides as targets for therapeutic intervention in immunological and inflammatory disorders, autoimmune diseases, pulmonary diseases, proliferative immune disorders, and cancer.

Abstract: EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing a biological sample from the mammal to the EGFR modulator and (b) measuring in the biological sample the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.

Abstract: A system and process that incorporates hardware and software as elements to be combined with procedures and processes to obtain, format, store, combine, control, display, record, and visualize dynamic scenarios by interacting with accurate, realistic models and actual events within, on, and above a three-dimensional surface to be observed or modeled. One application provides a user-manipulated large-scale dynamic display of systems testing in a real world environment for real time visualization by test personnel. The Global Visualization Process (GVP) system is an integrated software solution for high-performance visualization. GVP software and process is capable of displaying extremely high resolution terrain models and imagery in real time over the entire surface of the planet, as well as a large number of moving entities and their associated graphical models. The system can display imagery at 2 cm/pixel, and infinitely detailed terrain in real time over the whole surface of a planet.

Abstract: Biomarkers having expression patterns that correlate with a response of cells to treatment with one or more cdk modulating agents, and uses thereof. Also provided are methods for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer that comprises administering an agent that modulates cdk activity.

Abstract: The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e.g., neoplastic cell growth, and especially breast and prostate cancers or tumors.

Abstract: The present invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), and doublestranded RNA (dsRNA) molecules capable of mediating RNA interference (RNAi) against E2F1 gene expression, useful in the treatment of cell cycle disorders, inflammatory conditions, reproductive disorders, cancers and any other condition that responds to modulation of E2F1 expression and/or activity.

Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siRNA), short interfering RNA (siRNA), and doublestranded RNA (dsRNA) molecules capable of mediating RNA interference (RNAi) against E2F1, NFkB, CREB-1, and/or CDC2A gene expression, useful in the treatment of cell cycle disorders, inflammatory conditions, reproductive disorders, cancers and any other condition that responds to modulation of E2F1, NFkB, CREB-1, and/or CDC2A expression and/or activity.

Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: A guitar pick having a key ring hole for selective attachment to a key ring, and also having a centrally-located disc constructed from non-slippery material, in order to prevent the pick from slipping from a user's fingers while the pick is being used to play a guitar. The key ring hole is lined on both the front and rear surfaces of the pick with a raised bushing, in order to prevent the key ring hole from cracking or splitting after repeated use. When not being used to play a guitar, the guitar pick may be stored upon the key ring, in order to prevent the pick from becoming misplaced.

Abstract: The present invention provides novel polynucleotides encoding a human phosphatase polypeptide, BMY_HPP13, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptide. The invention further relates to diagnostic and therapeutic methods for applying this novel human phosphatase polypeptide to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: A system and process that incorporates hardware and software as elements to be combined with procedures and processes to obtain, format, store, combine, control, display, record, and visualize dynamic scenarios by interacting with accurate, realistic models and actual events within, on, and above a three-dimensional surface to be observed or modeled. One application provides a user-manipulated large-scale dynamic display of systems testing in a real world environment for real time visualization by test personnel. The Global Visualization Process (GVP) system is an integrated software solution for high-performance visualization. GVP software and process is capable of displaying extremely high resolution terrain models and imagery in real time over the entire surface of the planet, as well as a large number of moving entities and their associated graphical models. The system can display imagery at 2 cm/pixel, and infinitely detailed terrain in real time over the whole surface of a planet.

Abstract: The present invention provides novel polynucleotides encoding K+Mbeta1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+Mbeta1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding HEAG2 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HEAG2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding K+betaM3 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+betaM3 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: The present invention provides novel polynucleotides encoding K+alphaM1 polypeptides, fragments and homologues thereof. The invention also provides novel polynucleotides encoding the K+alphaM1 variant polypeptides, K+alphaM1.v1 and K+alphaM1.v2, in addition to fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel K+alphaM1, K+alphaM1.v1, and K+alphaM1.v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.